Physician profile

Luis Jimenez Berroa

San Juan, PR

NPI 1437142403

$2,528.46

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$610.69

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $554.70 2019-2024 Eliquis
Boehringer Ingelheim Pharmaceuticals, INC. $550.15 2019-2022
Astrazeneca Pharmaceuticals LP $523.77 2019-2023 Farxiga
Janssen Pharmaceuticals, INC $487.45 2019-2023 Xarelto
Merck Sharp & Dohme LLC $217.47 2019-2023 Zerbaxa, Recarbrio
Sanofi-Aventis U.S. LLC $106.25 2019
Abbott Laboratories $49.45 2024 Jot Dx
Pbg Puerto Rico LLC $25.00 2023
Novo Nordisk INC $14.22 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Luis Jimenez Berroa

$2,528.46

in general payments reported 2019-2025

Years
2019-2024
Top company
E.R. Squibb & Sons, L.L.C.

https://glasscript.com/doctor/64433/luis-jimenez-berroa

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.